Marina Garassino
Overview
Explore the profile of Marina Garassino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Catania C, Manglaviti S, Zucali P, Perrino M, Ruffini E, Di Tommaso L, et al.
Cancers (Basel)
. 2025 Jan;
17(2.
PMID: 39858021
Background: thymic basaloid carcinoma (BTC) is an extremely rare tumor, and very little data are available on BTC's biology, clinical behavior, drug sensitivity, and patient outcomes. Methods: We performed a...
3.
Ahn M, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al.
J Clin Oncol
. 2024 Sep;
43(3):260-272.
PMID: 39250535
Purpose: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC)....
4.
Boyer M, Hui R, Urban D, Clingan P, Su W, Devaux C, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1250.
PMID: 39054462
Background: The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygenase 1...
5.
Gridelli C, Peters S, Mok T, Garassino M, Paz-Ares L, Attili I, et al.
Lung Cancer
. 2023 Dec;
187:107441.
PMID: 38141488
Background: The combination of platinum-based chemotherapy with immune-checkpoint inhibitors (ICIs) is a standard of care option in the front-line treatment of advanced non-small cell lung cancer (NSCLC). Positive efficacy and...
6.
Le X, Paz-Ares L, Meerbeeck J, Viteri S, Galvez C, Smit E, et al.
Cell Rep Med
. 2023 Nov;
4(11):101280.
PMID: 37944528
High-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor,...
7.
Campochiaro C, Farina N, Tomelleri A, Ferrara R, Viola S, Lazzari C, et al.
Eur J Intern Med
. 2022 Jul;
103:95-99.
PMID: 35821192
Objective: Immune-related adverse events (irAEs) due to immune checkpoint inhibitors are responsible for a considerable burden of morbidity and mortality. Predictors of severity of rheumatic irAEs have not been identified...
8.
Le X, Cornelissen R, Garassino M, Clarke J, Tchekmedyian N, Goldman J, et al.
J Clin Oncol
. 2021 Nov;
40(7):710-718.
PMID: 34843401
Purpose: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene ( or ) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib,...
9.
Filippi A, Garassino M, Shirvani S, Feldman J, Higgins K
Lung Cancer
. 2021 Nov;
162:203-206.
PMID: 34742582
No abstract available.
10.
Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, Luca G, et al.
Eur J Intern Med
. 2021 Aug;
93:87-94.
PMID: 34391591
Objective: Research is moving towards a more personalized management of immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI). Our objective was to evaluate the efficacy and safety of...